



IBA Notice of Half Year 2022 Results and Conference Call

*HY22 results meeting to take place as a hybrid event on
Wednesday, 31 August 2022 at 3pm CEST*

Louvain-la-Neuve, Belgium, 11 July 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its consolidated results for the half year 2022 on **Wednesday, 31 August 2022 at 7am CEST**.

Conference Call Information

Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a hybrid event, including a conference call and webcast, conducted in English, to present the half year results, followed by a Q&A session.

The conference call will be held on **Wednesday, 31 August 2022 at 3pm CEST / 2pm BST / 9am EDT / 6am PDT** as a Teams webinar and can be accessed [online on this link](#).

If you would like to join by phone only, please dial (Phone conference ID 495 140 424#):

| | |
|----------|-------------------|
| Belgium: | +32 2 890 97 20 |
| UK: | +44 20 3321 5200 |
| NL: | +31 20 708 6901 |
| LU: | +352 27 87 00 02 |
| US: | +1 347-991-7591 |
| FR: | +33 1 70 99 53 51 |

The presentation will be available on [IBA's investor relations](#) website and on: <https://www.iba-worldwide.com/content/iba-half-year-results-2022-press-release-and-presentation> shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

For participants who do not have the Teams application installed, please follow the process described in [this link](#) to access the conference.

ENDS



About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,700 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange Euronext (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli

Chief Financial Officer

+32 10 475 890

Investorrelations@iba-group.com

Olivier Lechien

Corporate Communication Director

+32 10 475 890

communication@iba-group.com

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

IBA@consilium-comms.com